Current and future biosimilars: potential practical applications in rheumatology

References

• Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology – “O brave new world.” Nat Rev Rheumatol. 2012;8(7):430–436.
   PubMed Web of Science ®Google Scholar
• Agarwal SK. Core management principles in rheumatoid arthritis to help guide managed care professionals. J Manag Care Pharm. 2011;17(9 Suppl B):S3–S8.
   Web of Science ®Google Scholar
• Lapadula G, Ferraccioli GF Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues. Clin Exp Rheumatol. 2012;30(4 Suppl 73): S102–S106.
   Web of Science ®Google Scholar
• Carey K. Biosimilars encircle Rituxan, US debates innovator exclusivity. Nat Biotechnol. 2011;29(3):177–178.
   PubMed Web of Science ®Google Scholar
• Dörner T, Strand V, Castañeda-Hernández G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72(3):322–328.
   PubMed Web of Science ®Google Scholar
• Huggett B, Hodgson J, Lähteenmäki R. Public biotech 2009 – the numbers. Nat Biotechnol. 2010;28(8):793–799.
   Web of Science ®Google Scholar
• Kirchhoff T, Ruof J, Mittendorf T, et al. Cost of illness in rheumatoid arthritis in Germany in 1997–1998 and 2002: cost drivers and cost savings. Rheumatology (Oxford). 2011;50(4):756–761.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs. 2011;71(12):1527–1536.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Approval of biosimilars in the USA – dead ringers? Lancet. 2012;379(9817):686.
   Web of Science ®Google Scholar
• Colbert RA, Cronstein BN. Biosimilars: the debate continues. Arthritis Rheum. 2011;63(10):2848–2850.
   PubMedGoogle Scholar
• Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation’s biosimilars program. N Engl J Med. 2011;365(5):385–388.
   PubMed Web of Science ®Google Scholar
• Azevedo VF, Felippe LR, Machado DM. Opinion of some Brazilian rheumatologists about biosimilars. Rev Bras Reumatol. 2011 ;51(6):667–671.
   Google Scholar
• Weise M, Bielsky MC, De Smet K, et al. Biosimilars – why terminology matters. Nat Biotechnol. 2011;29(8):690–693.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Rockville (MD): FDA; 2012. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM291134.pdf. Accessed June 12, 2013.
   Google Scholar
• Jelkmann W Biosimilar epoetins and other “follow-on” biologic s: update on the European experiences. Am JHematol. 2010;85(10):771–780.
   Web of Science ®Google Scholar
• Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011;13(3):112.
   Web of Science ®Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf. Accessed April 19, 2013.
   Google Scholar
• Revers L, Furczon E. An introduction to biologics and biosimilars. Part I: Biologics: what are they and where do they come from? Can Pharmacists J. 2010;143(3):134–139.
   Google Scholar
• Schellekens H. Biosimilar therapeutics-what do we need to consider? NDTPlus. 2009;2 Suppl 1:i27–i36.
   Google Scholar
• Russell AS, Ahluwalla V, Barnabe C, et al. Subsequent entry biologics/ biosimilars: a viewpoint from Canada. Clin Rheumatol. 2012;31(9):1289–1292.
   Web of Science ®Google Scholar
• Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72(3):315–318.
   PubMed Web of Science ®Google Scholar
• Schiestl M, Stangler T, Torella C, Cepeljnik, T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310–312.
   PubMed Web of Science ®Google Scholar
• McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405–417.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA issues draft guidance on biosimilar product development [press release]. Rockville (MD): FDA; February 9, 2012. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm291232.htm. Accessed April 19, 2013.
   Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. Accessed April 19, 2013.
   Google Scholar
• Mysler E, Scheinberg M. Biosimilars in rheumatology: a view from Latin America. Clin Rheumatol. 2012;31(9):1279–1280.
   Web of Science ®Google Scholar
• US Food and Drug Administration. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. 2012. Available from: http://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM273001.pdf. Accessed April 19, 2013.
   Google Scholar
• Braido F, Holgate S, Canonica GW. From “blockbusters” to “biosimilars”: an opportunity for patients, medical specialists and health care providers. Pulm Pharmacol Ther. 2012;25(6):483–486.
   PubMed Web of Science ®Google Scholar
• Celltrion Healthcare. CT-P13 clinical trial. Available from: http://www.celltrionhealthcare.com/products/ct-p13/patient/product/product.asp. Accessed April 4, 2013.
   Google Scholar
• Park W, Hrycaj P, Kovalenko V et al. A randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics safety, and efficacy of CT-P13 and Infliximab in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis. 2012;71 Suppl 3:111.
   Google Scholar
• Yoo D, Miranda P, Piotrowski M, et al. A randomized, double-blind, phase 3 study demonstrates clinical equivalence of CT-P13 to infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis [abstract]. Ann Rheum Dis. 2012;71 Suppl 3:359.
   Google Scholar
• [No authors listed]. Celltrion’s first biosimilar antibody is about to reach the market. Biosimilar News. 2012. Available from: http://www.biosimilarnews.com/celltrions-first-biosimilar-antibody-is-about-to- reach-the-market. Accessed April 4, 2013.
   Google Scholar
• Burgos-Vargas R, Catoggio LJ, Galarza-Maldonado C, Ostojich K, Cardiel MH. Current therapies in rheumatoid arthritis: a Latin American perspective. Reumatol Clin. 2013;9(2):106–112.
   Google Scholar
• Nature Publishing Group. Similarity trials [editorial]. Nat Biotechnol. 2011;29(1):1.
   Google Scholar